Press Release Details

Cerus to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 17, 2015

September, 10 2015

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that William “Obi” Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Morgan Stanley Healthcare Unplugged Conference at 8:00 AM ET on Thursday, September 17, 2015.

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Source: Cerus Corporation

Investor Relations Contacts:

Cerus Corporation

Stacey Leanos, 925-288-6137

Associate Director, Investor & Public Relations

Lainie Corten, 925-288-6137

Vice President, Global Marketing & Investor Relations

ir@cerus.com

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600